| 1 |
Griffin MD, Elliman SJ, Cahill E, et al. Concise review: adult mesenchymal stromal cell therapy for inflammatory diseases: how well are we joining the dots?[J]. Stem Cells, 2013, 31(10):2033-2041.
|
| 2 |
Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside[J]. Gut, 2012, 61(6):918-932.
|
| 3 |
Saldanha-Araujo F, Ferreira FI, Palma PV, et al. Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes[J]. Stem Cell Res, 2011, 7(1):66-74.
|
| 4 |
Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo[J]. Exp Hematol, 2002, 30(1):42-48.
|
| 5 |
Takebe Y, Tatehara S, Fukushima TA, et al. Cryopreservation method for the effective collection of dental pulp stem cells[J]. Tissue Eng Part C Methods, 2017, 23(5):251-261.
|
| 6 |
Bellavia M, Altomare R, Cacciabaudo F, et al. Towards an ideal source of mesenchymal stem cell isolation for possible therapeutic application in regenerative medicine[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2014, 158(3):356-360.
|
| 7 |
Stoltz JF, De Isla N, Li YP, et al. Stem cells and regenerative medicine: myth or reality of the 21th century[J]. Stem Cells Int, 2015 (2015):1-19.
|
| 8 |
Ye JS, Su XS, Stoltz JF, et al. Signalling pathways involved in the process of mesenchymal stem cells differentiating into hepatocytes[J]. Cell Prolif, 2015, 48(2):157-165.
|
| 9 |
Reppel L, Margossian T, Yaghi L, et al. Hypoxic culture conditions for mesenchymal stromal/stem cells from wharton's jelly: a critical parameter to consider in a therapeutic context[J]. Curr Stem Cell Res Ther, 2014, 9(4):306-318.
|
| 10 |
Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement [J]. Cytotherapy, 2005, 7(5):393-395.
|
| 11 |
Kavanagh H, Mahon BP. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells[J]. Allergy, 2011, 66(4):523-531.
|
| 12 |
Caplan AI. Why are MSCs therapeutic? New data: new insight[J]. J Pathol, 2009, 217(2):318-324.
|
| 13 |
Sun YQ, Deng MX, He J, et al. Human pluripotent stem cell-derived mesenchymal stem cells prevent allergic airway inflammation in mice [J]. Stem Cells, 2012, 30(12):2692-2699.
|
| 14 |
Han KH, RO H, Hong JH, et al. Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response[J]. Transpl Immunol, 2011, 25(1):7-15.
|
| 15 |
Krampera M, Glennie S, Dyson J, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide[J]. Blood, 2003, 101(9):3722-3729.
|
| 16 |
English K, Ryan JM, Tobin L, et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+ CD25(High) forkhead box P3+ regulatory T cells[J]. Clin Exp Immunol, 2009, 156(1):149-160.
|
| 17 |
Raicevic G, Najar M, Najimi M, et al. Influence of inflammation on the immunological profile of adult-derived human liver mesenchymal stromal cells and stellate cells[J]. Cytotherapy, 2015, 17(2):174-185.
|
| 18 |
Delarosa O, Lombardo E, Beraza AA, et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells[J]. Tissue Eng Part A, 2009, 15(10):2795-2806.
|
| 19 |
Sanchez-AI, Alvarez-LI, Diez-CM, et al. Uptake and delivery of antigens by mesenchymal stromal cells[J]. Cytotherapy, 2013, 15(6):673-678.
|
| 20 |
Ren G, Zhao X, Zhang L, et al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression[J]. J Immunol, 2010, 184(5):2321-2328.
|
| 21 |
Hemeda H, Jakob M, Ludwig AK, et al. Interferon-gamma and tumor necrosis factor-alpha differentially affect cytokine expression and migration properties of mesenchymal stem cells[J]. Stem Cells Dev, 2010, 19(5):693-706.
|
| 22 |
Maby-El Hajjami H, Amé-Thomas P, Pangault C, et al. Functional alteration of the lymphoma stromal cell niche by the cytokine context: role of indoleamine-2,3 dioxygenase[J]. Cancer Res, 2009, 69(7):3228-3237.
|
| 23 |
Opitz CA, Litzenburger UM, Lutz C, et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R[J]. Stem Cells, 2009, 27(4):909-919.
|
| 24 |
Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production [J]. Nat Med, 2009, 15(1):42-49.
|
| 25 |
Wang Y, Chen XD, Cao W, et al. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications[J]. Nat Immunol, 2014, 15(11):1009-1016.
|
| 26 |
Manuela B, Alessandra F, Rosa L, et al. The immunosuppressive effect of mesenchymal stromal cells on B lymphocytes is mediated by membrane vesicles[J]. Cell Transplant, 2013, 22(2):369-379.
|
| 27 |
Mokarizadeh A, Delirezh N, Morshedi A, et al. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling[J]. Immunol Lett, 2012, 147(1/2):47-54.
|
| 28 |
Yang J, Liu XX, Fan H, et al. Extracellular vesicles derived from bone marrow mesenchymal stem cells protect against experimental colitis via attenuating colon inflammation,oxidative stress and apoptosis[J]. PLoS One, 2015, 10(10):e0140551.
|
| 29 |
Hashemian SJ, Kouhnavard M, Nasli-Esfahani E. Mesenchymal stem cells: rising concerns over their application in treatment of type one diabetes mellitus[J]. J Diabetes Res, 2015 (2015):675103.
|
| 30 |
Tatara R, Ozaki K, Kikuchi Y, et al. Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation[J]. Cytotherapy, 2011, 13(6):686-694.
|
| 31 |
Ghannam S, Pène J, Moquet-Torcy G, et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype[J]. J Immunol, 2010, 185(1):302-312.
|
| 32 |
Oukka M. Th17 cells in immunity and autoimmunity[J]. Ann Rheum Dis, 2008, 67(3):26-29.
|
| 33 |
Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)- 17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat[J]. Nat Immunol, 2008, 9(6):641-649.
|
| 34 |
Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor[J]. Nature, 2008, 453(7191):65-71.
|
| 35 |
Liu C, Qian W, Qian Y, et al. Act1, a U-box E3 ubiquitin ligase for IL- 17 signaling [J]. Sci Signal, 2009, 2(92):ra63.
|
| 36 |
Andolfi G, Fousteri G, Rossetti M, et al. Enforced IL-10 expression confers type 1 regulatory T cell (Tr1) phenotype and function to human CD4(+) T cells[J]. Mol Ther, 2012, 20(9):1778-1790.
|
| 37 |
Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg- mediated T cell suppression[J]. Front Immunol, 2012, 3(21):51.
|
| 38 |
Hongo D, Tang XB, Dutt S, et al. Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants[J]. Blood, 2012, 119(6):1581-1589.
|
| 39 |
Gondek DC, Devries V, Nowak EC, et al. Transplantation survival is maintained by granzyme B+ regulatory cells and adaptive regulatory T cells[J]. J Immunol, 2008, 181(7):4752-4760.
|
| 40 |
Zhu XM, Shi YZ, Cheng M, et al. Serum IL-6, IL-23 profile and Treg/ Th17 peripheral cell populations in pediatric patients with inflammatory bowel disease[J]. Pharmazie, 2017, 72(5):283-287.
|
| 41 |
Ju JH, Heo YJ, Cho ML, et al. Modulation of STAT-3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells[J]. Arthritis Rheum, 2012, 64(11):3543-3552.
|
| 42 |
Fonseca-Camarillo G, Yamamoto-Furusho JK. Immunoregulatory pathways involved in inflammatory bowel disease[J]. Inflamm Bowel Dis, 2015, 21(9):2188-2193.
|
| 43 |
Li J, Glover SC. Innate lymphoid cells in inflammatory bowel disease [J]. Arch Immunol Ther Exp (Warsz), 2018, 66(6):415-421.
|
| 44 |
Li J, Ueno A, Gasia MF, et al. Profiles of lamina propria T helper cell subsets discriminate between ulcerative colitis and crohn's disease[J]. Inflamm Bowel Dis, 2016, 22(8):1779-1792.
|
| 45 |
Monteleone I, Sarra M, Pallone F, et al. Th17-Related cytokines in inflammatory bowel diseases: friends or Foes?[J]. Curr Mol Med, 2012, 12(5):592-597.
|
| 46 |
Salas A, Panes JI. Regulatory T cells for treatment of Crohn's disease [J]. Nat Rev Gastroenterol Hepatol, 2015, 12(6):315-316.
|
| 47 |
Ogino H, Nakamura K, Ihara E, et al. CD4(+)CD25(+) regulatory T cells suppress Th17-Responses in an experimental colitis model[J]. Dig Dis Sci, 2011, 56(2):376-386.
|
| 48 |
Menning A, Loddenkemper C, Westendorf AM, et al. Retinoic acid-induced gut tropism improves the protective capacity of Treg in acute but not in chronic gut inflammation[J]. Eur J Immunol, 2010, 40(9):2539-2548.
|
| 49 |
Jiang XP, Huang XL, Yang ZP, et al. Iguratimod ameliorates inflammatory responses by modulating the Th17/Treg paradigm in dextran sulphate sodium-induced murine colitis[J]. Mol Immunol, 2018, 93(1):9-19.
|
| 50 |
Lim SM, Jeong JJ, Jang SE, et al. A mixture of the probiotic strains Bifidobacterium longum CH57 and Lactobacillus brevis CH23 ameliorates colitis in mice by inhibiting macrophage activation and restoring the Th17/Treg balance[J]. J Funct Foods, 2016, 27: 295-309.
|
| 51 |
Ma Y, Wang Z, Zhang A, et al. Human placenta-derived mesenchymal stem cells ameliorate GVHD by modulating Th17/Tr1 balance via expression of PD-L2[J]. Life Sci, 2018, 214(1):98-105.
|
| 52 |
Kong QF, Sun B, Bai SS, et al. Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-beta[J]. J Neuroimmunol, 2009, 207(1-2):83-91.
|
| 53 |
Cheng Q, Zhang Z, Zhang S, et al. Human umbilical cord mesenchymal stem cells protect against ischemic brain injury in mouse by regulating peripheral immunoinflammation[J]. Brain Res, 2015, 1594(1):293-304.
|
| 54 |
Huang Y, Chen Z. Inflammatory bowel disease related innate immunity and adaptive immunity[J]. Am J Transl Res, 2016, 8(6):2490-2497.
|
| 55 |
刘星星，范恒，唐庆, 等. 过表达CXCR4的间充质干细胞缓解实验性结肠炎[J]. 世界华人消化杂志, 2016 (8):1233-1240.
|
| 56 |
Fu ZW, Zhang ZY, Ge HY. Mesenteric injection of adipose-derived mesenchymal stem cells relieves experimentally-induced colitis in rats by regulating Th17/Treg cell balance[J]. Am J Transl Res, 2018, 10(1):54-66.
|
| 57 |
González MA, Gonzalez-Rey E, Rico L, et al. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses[J]. Gastroenterology, 2009, 136(3):978-989.
|
| 58 |
Bandzar S, Gupta S, Platt MO. Crohn's disease: A review of treatment options and current research [J]. Cell Immunol, 2013, 286(1/2):45-52.
|
| 59 |
Akiyama K, Chen C, Wang D, et al. Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis [J]. Cell Stem Cell, 2012, 10(5):544-555.
|